Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

Sanofi has paid the upfront fee and committed to discovery, development and commercial milestones of over $400 million to get ...

The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend ...

Bristol Myers Squibb’s Cobenfy achieved an 8.4-point PANSS improvement over placebo after five weeks in a phase 3 trial that ...

The job cuts reflect the normal maturation of companies such as Alameda-based Scribe, which is moving from a preclinical to ...

MRT-5421 is under clinical development by Sanofi and currently in Phase II for Unspecified Influenza Virus Infections.

Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.

Vir Biotechnology (CIR) stock surged 42% after positive Phase 1 data for two antitumor agents developed using Sanofi's (SNY) ...

On Thursday, Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab) subcutaneous formulation via an on-body delivery system ...